BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawaguchi T, Nakano D, Okamura S, Shimose S, Hayakawa M, Niizeki T, Koga H, Torimura T. Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus. Hepatol Res 2019;49:479-86. [PMID: 30180287 DOI: 10.1111/hepr.13247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nakano D, Kawaguchi T, Tsutsumi T, Hayakawa M, Yoshio S, Koga H, Torimura T. Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells. JGH Open. [DOI: 10.1002/jgh3.12730] [Reference Citation Analysis]
2 Yin L, Xia Y, Xu P, Zheng W, Gao Y, Xie F, Ji Z. Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death. Oncol Rep 2020;44:477-86. [PMID: 32468056 DOI: 10.3892/or.2020.7622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zheng Y, Liao N, Wu Y, Gao J, Li Z, Liu W, Wang Y, Li M, Li X, Chen L, Zhang W, Zhao B. High expression of B7‑H2 or B7‑H3 is associated with poor prognosis in hepatocellular carcinoma. Mol Med Rep 2019;19:4315-25. [PMID: 30942404 DOI: 10.3892/mmr.2019.10080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
4 Hoerner CR, Miao SY, Hsieh JJ, Fan AC. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities. Cancer J 2020;26:407-18. [PMID: 32947309 DOI: 10.1097/PPO.0000000000000472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
6 Xie Z, Wang F, Lin L, Duan S, Liu X, Li X, Li T, Xue M, Cheng Y, Ren H, Zhu Y. An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett 2020;495:200-10. [PMID: 32931885 DOI: 10.1016/j.canlet.2020.09.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Lau KTK, Ng L, Wong JWH, Loong HHF, Chan WWL, Lee CH, Wong CKH. Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review. Rev Endocr Metab Disord 2021. [PMID: 34272645 DOI: 10.1007/s11154-021-09675-9] [Reference Citation Analysis]
8 Zhong J, Sun P, Xu N, Liao M, Xu C, Ding Y, Cai J, Zhang Y, Xie W. Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin. Biochem Pharmacol 2020;175:113856. [PMID: 32061772 DOI: 10.1016/j.bcp.2020.113856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]